Physician profile
Rami Atallah
NPI 1750819702
$2,974.82
in general payments reported to CMS, 2019-2025
33 companies · $1,312 in 2025
The $1,312 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $124 · 2023: $375 · 2024: $1,164 · 2025: $1,312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,704 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $120 · Education: $26.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,703.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $120.00 |
| Education | $26.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $480.78 | 2023-2025 | |
| Pfizer INC. | $297.30 | 2023-2024 | |
| Seagen INC. | $222.61 | 2020-2023 | Tukysa, Adcetris, Padcev |
| Daiichi Sankyo INC. | $216.82 | 2023-2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $172.02 | 2024-2025 | Keytruda, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $156.38 | 2023-2025 | Opdivo, Opdualag |
| Janssen Biotech, INC. | $137.20 | 2024-2025 | Rybrevant, Carvykti, Darzalex |
| Abbvie INC. | $137.09 | 2024-2025 | |
| Celgene Corporation | $130.90 | 2023-2025 | Reblozyl, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $101.43 | 2023-2025 | Ninlaro, Fruzaqla |
| Beone Medicines USA, INC. | $80.51 | 2025 | Tevimbra, Brukinsa |
| Array Biopharma INC | $78.96 | 2024-2025 | Braftovi, Mektovi, Tukysa |
| Stemline Therapeutics INC. | $72.80 | 2024-2025 | Orserdu |
| Gilead Sciences, INC. | $68.96 | 2025 | Trodelvy |
| Lilly USA, LLC | $64.39 | 2025 | Verzenio, Jaypirca |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $64.15 | 2025 | Jemperli, Blenrep, Ojjaara |
| Astellas Pharma US INC | $44.23 | 2024-2025 | Xtandi |
| Deciphera Pharmaceuticals INC. | $43.27 | 2024-2025 | Qinlock, Romvimza |
| Servier Pharmaceuticals LLC | $39.17 | 2024-2025 | |
| Mirati Therapeutics, INC. | $38.22 | 2023-2024 | Krazati |
| Pharmacyclics LLC, An Abbvie Company | $37.98 | 2023 | Imbruvica |
| Beigene USA, INC. | $37.59 | 2024-2025 | Tevimbra, Brukinsa |
| Regeneron Healthcare Solutions, INC. | $34.02 | 2024-2025 | Libtayo |
| Sun Pharmaceutical Industries INC. | $28.00 | 2025 | |
| Alexion Pharmaceuticals, INC. | $23.20 | 2025 | Ultomiris |
| Karyopharm Therapeutics INC. | $23.06 | 2023 | Xpovio |
| Sobi, INC | $22.84 | 2025 | |
| Adaptive Biotechnologies Corporation | $22.61 | 2025 | Clonoseq |
| Aveo Pharmaceuticals, INC. | $22.19 | 2024 | |
| Fennec Pharmaceuticals, INC. | $21.95 | 2025 | Fyarro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.76 | 2025 | |
| Taiho Oncology, INC. | $18.54 | 2025 | |
| Eisai INC. | $16.89 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rami Atallah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.